Teva to Pay $35M in QVAR Antitrust Case, Clearing Path for Generics

SAN FRANCISCO, CA – May 01, 2026 – Teva Pharmaceutical Industries Ltd. has agreed to a $35 million settlement to resolve a class action lawsuit alleging the company illegally stifled competition for its popular asthma inhalers, QVAR® and QVAR RediHaler®. The settlement, which awaits final court approval, promises not only financial compensation for millions of consumers and insurers but also a significant structural change aimed at paving the way for more affordable generic alternatives.

The lawsuit, brought forth by law firms including Berman Tabacco and Hilliard Shadowen LLP, accused the pharmaceutical giant of orchestrating a multi-pronged scheme to maintain its monopoly and charge inflated prices for the essential asthma medication. While Teva denies all allegations of wrongdoing, the settlement marks a pivotal moment for patients and payors who have borne the cost of the branded drug for over a decade.

A Decade of Alleged Market Manipulation

At the core of the lawsuit, filed in the U.S. District Court for the District of Massachusetts, are accusations of anti-competitive practices designed to delay the entry of generic versions of QVAR. Plaintiffs alleged that Teva engaged in a strategy known as "product hopping." This tactic involves a brand-name manufacturer making minor, non-substantive changes to a drug and then pulling the older version from the market. The goal is to force patients to switch to the new, patent-protected product, thereby preventing pharmacists from substituting a cheaper generic equivalent of the original drug.

According to the complaint, Teva executed this strategy twice. First, in 2014, it discontinued its original QVAR inhaler after adding a dose counter. Then, after gaining FDA approval for the QVAR RediHaler in 2017—a breath-actuated device—it ceased all sales of the previous QVAR version. Plaintiffs argued these moves were not driven by patient benefit but by a desire to disrupt the market and create new patent hurdles for would-be generic competitors.

Furthermore, the lawsuit contended that Teva engaged in "sham litigation" and improperly listed patents in the FDA's public database, known as the "Orange Book," to trigger automatic 30-month stays on the approval of generic applications. The complaint also pointed to an alleged "pay-for-delay" agreement, where Teva purportedly paid rival manufacturer Amneal Pharmaceuticals to postpone the launch of its generic QVAR version, which had been ready for market entry since 2020. These combined actions, the lawsuit claimed, allowed Teva to unlawfully extend its monopoly and overcharge for its products for years.

How Consumers and Insurers Can Claim Their Share

The $35 million settlement fund is intended to provide financial restitution to those who purchased or reimbursed for the inhalers. The class includes individuals and entities in 35 states and the District of Columbia who bought QVAR® or QVAR RediHaler® between January 1, 2015, and July 31, 2025.

Under the proposed plan of allocation, 79.3% of the net settlement fund will be distributed to third-party payors, such as insurance companies and health plans, while 20.7% is designated for individual consumers. To receive a payment, eligible class members must submit a valid claim form by the deadline of July 31, 2026.

Claim forms and detailed information are available on the official settlement website, www.QVARAntitrustSettlement.com. The final payout for each claimant will depend on several factors, including the total amount spent on the inhalers, the number of valid claims submitted, and the total value of all claims. Plaintiffs' counsel noted that the $35 million payment represents approximately 11% of the estimated damages, describing it as an "excellent result" considering the significant risks and costs of protracted litigation.

Before any funds are distributed, the settlement must receive final approval from the court. A Fairness Hearing is scheduled for August 5, 2026. At this hearing, the court will also consider requests for attorneys' fees, which may be up to one-third of the fund (approximately $11.5 million), along with litigation expenses and service awards for the class representatives.

Paving the Way for Generic Competition

Perhaps the most impactful component of the settlement is Teva's agreement to remove six key patents associated with QVAR from the FDA's Orange Book. This move directly addresses one of the primary barriers that has prevented generic versions from reaching the market. When a company lists patents in the Orange Book, it forces generic manufacturers into a complex and often lengthy legal process to challenge those patents, which can include the 30-month stay of FDA approval.

By delisting these patents, Teva is effectively clearing a significant legal hurdle. This action is particularly notable because the U.S. Federal Trade Commission (FTC) had previously urged Teva to delist the patents, but the company had not complied. The success of the private class action lawsuit in achieving this goal underscores the power of such litigation in enforcing antitrust laws.

The removal of these patents could substantially accelerate the timeline for one or more generic QVAR products to receive FDA approval and enter the market. The introduction of generic competition typically leads to a dramatic reduction in drug prices, which would directly benefit asthma patients and the healthcare system as a whole by increasing access to more affordable treatment options.

Broader Context of Pharmaceutical Scrutiny

This settlement does not exist in a vacuum. It comes at a time when Teva and other pharmaceutical companies are facing intense scrutiny over their pricing and business practices. In August 2023, Teva reached a deferred prosecution agreement with the Department of Justice, agreeing to pay a $225 million fine to settle criminal charges related to generic drug price-fixing. Previously, in 2020, the company paid $54 million to resolve allegations that it used speaker programs as a front to pay illegal kickbacks to doctors for prescribing its medications.

The QVAR settlement adds to a growing body of legal precedent pushing back against anti-competitive strategies like product hopping and pay-for-delay schemes. For patients who rely on daily medication for chronic conditions like asthma, the outcome of these legal battles is not just academic. It directly affects the affordability and accessibility of their care. The final approval hearing on August 5, 2026, will be the next critical step in closing this chapter and potentially opening a new one characterized by greater competition and lower costs for this essential asthma medication.